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Abstract
Introduction: The objective was to evaluate the changes in S100A8 S100A9, and their complex (S100A8/S100A9)
in cartilage during the onset of osteoarthritis (OA) as opposed to inflammatory arthritis.
Methods: S100A8 and S100A9 protein localization were determined in antigen-induced inflammatory arthritis in
mice, mouse femoral head cartilage explants stimulated with interleukin-1 (IL-1), and in surgically-induced OA in
mice. Microarray expression profiling of all S100 proteins in cartilage was evaluated at different times after initiation
of degradation in femoral head explant cultures stimulated with IL-1 and surgically-induced OA. The effect of
S100A8, S100A9 or the complex on the expression of aggrecan (Acan), collagen II (Col2a1), disintegrin and
metalloproteases with thrombospondin motifs (Adamts1, Adamts 4 &Adamts 5), matrix metalloproteases (Mmp1,
Mmp3, Mmp13 &Mmp14) and tissue inhibitors of metalloproteinases (Timp1, Timp2 &Timp3), by primary adult ovine
articular chondrocytes was determined using real time quantitative reverse transcription polymerase chain reaction
(qRT-PCR).
Results: Stimulation with IL-1 increased chondrocyte S100a8 and S100a9 mRNA and protein levels. There was
increased chondrocyte mRNA expression of S100a8 and S100a9 in early but not late mouse OA. However, loss of
the S100A8 staining in chondrocytes occurred as mouse OA progressed, in contrast to the positive reactivity for
both S100A8 and S100A9 in chondrocytes in inflammatory arthritis in mice. Homodimeric S100A8 and S100A9, but
not the heterodimeric complex, significantly upregulated chondrocyte Adamts1, Adamts4 and Adamts 5, Mmp1,
Mmp3 and Mmp13 gene expression, while collagen II and aggrecan mRNAs were significantly decreased.
Conclusions: Chondrocyte derived S100A8 and S100A9 may have a sustained role in cartilage degradation in
inflammatory arthritis. In contrast, while these proteins may have a role in initiating early cartilage degradation in
OA by upregulating MMPs and aggrecanases, their reduced expression in late stages of OA suggests they do not
have an ongoing role in cartilage degradation in this non-inflammatory arthropathy.
Introduction
S100 proteins are low molecular weight (9 to 14 kDa)
intracellular calcium-binding proteins that control key
cellular pathways including regulation of the cytoskeleton
[1], cell migration and adhesion [2], and host oxidative
defense [3,4]. Some S100 proteins have also been demon-
strated to have important extracellular pro-inflammatory
effects and cytokine-like activities in addition to their
intracellular functions. When released from cells,
S100A8, S100A9, S100A11, and S100A12 act as uncon-
ventional inflammatory cytokines [5,6]. Therefore, not
only the expression of these proteins by cells, but also
their release into the extracellular environment may have
important implications on their activity in a given tissue.
S100A8 and S100A9 are found intracellularly in gran-
ulocytes, monocytes, and early differentiation stages of
macrophages [7,8]. A clear increase and role for S100A8
a n dS 1 0 0 A 9i nt h es y n o v i u ma n dm a c r o p h a g e si n
inflammatory arthritis has been established [9,10]. Extra-
cellular S100A8 is considered a pro-inflammatory mole-
cule because of its effect on cytokine synthesis [11] and
upregulation of destructive matrix metalloproteinases
(MMP) and disintegrin and metalloproteases with
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phages [10,12]. In contrast, S100A9 alone was previously
shown not to activate phagocytes and, when it forms a
complex with S100A8, to decrease the activity of this
S100 protein [11]. Chondrocytes have also been shown
to express S100A8 and S100A9 [13] and their upregula-
tion following stimulation with IL-1 and oncostatin-M,
suggested a possible role in cartilage repair or inflamma-
tion-induced degradation [14]. Recently, increased
S100A8 and S100A9 staining of chondrocytes in inflam-
matory arthropathies in mice and humans was reported
[9]. This same study also demonstrated that extracellular
S100A8 stimulated expression and activity of various
matrix-degrading metalloproteinases by a chondrocyte
cell line, and aggrecanolysis in mouse patella explant
cultures [9]. These results suggested that in inflamma-
tory arthritis, extracellular S100A8 secreted from inflam-
matory cells or the chondrocytes themselves may be an
important mediator of cartilage matrix degradation.
In contrast to the significant role of infiltrating inflam-
matory cells and synovial pannus in rheumatoid arthritis
(RA), cartilage breakdown in osteoarthritis (OA) is dri-
ven primarily by the chondrocytes. Although considered
to be a non-inflammatory arthropathy, a role for chon-
drocyte-derived cytokines in maintaining elevated pro-
teolysis of aggrecan and collagen in end-stage human
OA cartilage has been demonstrated [15]. To date, how-
ever, the changes in S100A8 and S100A9 expression and
protein localization and the potential role of these two
proteins in cartilage destruction during the onset and
progression of OA as opposed to inflammatory arthro-
pathies has not been investigated. Furthermore, although
it has been shown that S100A8 can induce catabolic
enzymes expression in chondrocyte cell lines [9], no
previous studies have established whether S100A8 has a
similar effect in primary adult articular chondrocytes or
if S100A9 or the S100A8/A9 complex has a similar
effect. We investigated the immunolocalization of
S100A8 and S100A9 in sections of antigen-induced
arthritis (AIA); the effect of IL-1a on S100a8 and
S100a9 expression and immunolocalization in mouse
cartilage explants in vitro;t h ein vivo expression and
immunolocalization of S100A8 and S100A9 in cartilage
during progressive cartilage destruction in an OA com-
pared with an inflammatory arthritis model in mice; and
the effect of S100A8 and S100A9 on the expression by
primary adult ovine articular chondrocytes of key extra-




All animal experimentation was conducted with
approval from the Royal North Shore Hospital Animal
Care and Ethics Committee (protocols 0051-005A and
0506-019A). OA was induced in 10-week-old male
C57BL6 mice by medial meniscal destabilization (MMD)
of the right knee [16]. Joints with no surgery or sub-
jected to sham-operation (exposure of the medial
menisco-tibial ligament but no transection) were used as
controls. Animals were sacrificed at 2, 4, 8 and 16 weeks
after surgery (n = 3 per time point) for histology and
immunohistology.
Additional 10 week-old C57BL6 male mice underwent
bilateral surgery with the right knee undergoing MMD
while the left knee underwent a sham-operation. Ani-
mals were sacrificed at one, two, and six weeks after
surgery (n = 7 per time point). The joints were dissected
to expose the articular cartilage, tibial epiphyses were
isolated and placed in RNA later containing 20% EDTA,
decalcified at 4°C for 72 hours and then embedded in
optimal cutting temperature (OCT) compound and
stored at -80°C. Serial 7 μm coronal cryo-sections were
fixed in ethanol, air-dried, and non-calcified medial
tibial plateau articular cartilage from previously assigned
areas of cartilage fibrillation and loss of toluidine blue
staining were microdissected and isolated using a Veri-
tas microdissection system (Molecular Devices, Sunny-
vale, CA, USA).
Mouse cartilage isolation and culture
Femoral head cartilage was isolated from 24-day-old
C57B6 wild type mice and cultured for two or four days
in serum-free medium with or without 10 ng/ml recom-
binant human IL-Ia (PeproTech, London, UK [17]. In
four-day cultures the media was changed after two days.
At termination, femoral heads were either stored at -20°
Ci nR N Al a t e r( A m b i o n ,A u s t i nT X ,U S A )p r i o rt o
RNA extraction or embedded in OCT and stored at -80°
C prior to immunostaining.
Chondrocyte isolation and culture
Chondrocytes from four-year-old ovine knee articular
cartilage were isolated by sequential pronase and col-
lagenase digestion and grown to confluence in serum-
containing media [18]. Cells were incubated overnight
in serum-free medium prior to stimulation for 24 hours
with serum-free medium containing 10
-7 or 10
-8 M
recombinant human S100A8, S100A9, or the complex
of both (n = 6 replicates/treatment). Recombinant
human S100A8, S100A9, or heterocomplex with no con-
taminating lipopolysaccharise (LPS) were expressed and
purified as described [13,19,20].
RNA extraction
At the termination of culture, ovine chondrocytes were
washed with PBS, and then lysed with TRIzol (Invitro-
gen Life Technologies, Mulgrave, Victoria, Australia).
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nitrogen-cooled tissue mill. Pulverised femoral heads
and micro-dissected cartilage from frozen sections of
sham or MMD-induced OA joints were extracted with
TRIzol. Total cellular RNA in TRIzol extracts was iso-
lated from all samples by RNeasy kit (Qiagen, Doncas-
ter, Victoria, Australia) including an on-column DNase I
(Qiagen, Doncaster, Victoria, Australia) digestion. RNA
was quantified using Sybrgreen (Molecular Probes, USA)
with 18S/28S rRNA as a standard (Sigma-Aldrich, Castle
Hill, NSW, Australia). Three femoral heads were pooled
to generate a representative RNA sample for each in
vitro treatment and were analysed by microarray expres-
sion profiling. Micro-dissected cartilage from three sepa-
rate joints was pooled to account for biological
variability, and provide a representative sample of sham
or MMD cartilage RNA at each time point for microar-
r a ya n a l y s i s .T h eR N Af r o mt h er e m a i n i n gf o u rs h a m
and MMD joints were analysed separately using quanti-
tative RT-PCR (qRT-PCR) for S100a8 and S100a9 to
verify the results from the microarray analysis.
Ovine chondrocyte quantitative reverse transcription
polymerase chain reaction
Changes in mRNA expression in cultured primary ovine
chondrocytes were quantified using real-time qRT-PCR
as previously described [21]. Reverse transcription (RT)
reactions were undertaken with 1 μg total RNA (Omnis-
cript RT kit, Qiagen, Doncaster, Victoria, Australia). All
samples underwent RT at the same time to avoid poten-
tial variations in experimental conditions. Aliquots of
cDNA were amplified by PCR using specific ovine pri-
mer sets (Table 1). All PCR reactions generated single
products with confirmed sequences (SUPAMAC, Sydney
University, NSW, Australia). The differentiated pheno-
type of control cultures of primary ovine chondrocytes
in monolayer was confirmed by examining gene expres-
sion relative to Gapdh. However, all ‘housekeeping’
genes evaluated (Gapdh, Actb, Hprt, ubiquitin) showed
differential regulation by S100 proteins (data not
shown). Therefore, to evaluate the changes induced by
S100A8, S100A9, or the heterocomplex, gene expression
in all cultures including controls was subsequently cor-
rected for total RNA [22] and the effect of added S100
proteins expressed as fold change from control cultures.
Mouse cartilage RNA amplification, microarray
hybridization and qRT-PCR
To quantify changes in all S100 mRNA in cultured mouse
femoral heads and micro-dissected tibial cartilage from
the OA model, linear amplification in one or two rounds,
respectively, was performed using the MessageAmp kit
Table 1 Ovine-specific real time PCR primer pair sequences, annealing temperatures and product size
Target gene Sequence Anneal temp (°C) Product size (bp) Accession number or
reference if published
Acan F - TCA CCA TCC CCT GCT ACT TCA TC
R - TCT CCT TGG AAA TGC GGC TC
58 105 [21]
Adamts1 F - CCA ACT GGA GCC ACA AAC ATT G
R - GGA CAG AGT GAA GTC GCC ATT C
55 126 [GenBank: XM_589626]
Adamts4 F - AAC TCG AAG CAA TGC ACT GGT
R - TGC CCG AAG CCA TTG TCT A
60 149 [44]
Adamts5 F - GCA TTG ACG CAT CCA AAC CC
R - CGT GGT AGG TCC AGC AAA CAG TTA C
55 97 [21]
Col2a1 F - TGA CCT GAC GCC CAT TCA TC
R - TTT CCT GTC TCT GCC TTG ACC C
55 154 [GenBank: X02420]
Mmp1 F - CAT TCT ACT GAC ATT GGG GCT CTG
R - TGA GTG GGA TTT TGG GAA GGT C
55 122 [GenBank: AF267156]
Mmp3 F - TCC CCC AGT TTC CCC TAA TG
R - GAT TTC TCC CCT CAG TGT GCT G
58 124 [GenBank: AF135232]
Mmp13 F - GGT GAC AGG CAG ACT TGA TGA TAA C
R - ATT TGG TCC AGG AGG GAA AGC G
58 349 [21]
Mmp14 R - CCC AGT GCT TGT CTC CTT TGA AG 56 126 [GenBank: AF267160]
Timp1 F - GGT TCA GTG CCT TGA GAG ATG C
R - GGG ATA GAT GAG CAG GGA AAC AC
57 265 [GenBank: S67450]
Timp2 F - ACT CTG GCA ACG ACA TCT ACG G
R - TCT TCT TCT GGG TGG CAC TCA G
57 261 [GenBank: M32303]
Timp3 F - CTT CCT TTG CCC TTC TCT ACC C
R - TCT GGT CAA CCC AAG CAT CG
57 286 [GenBank: NM_174473]
Gapdh F - CCT GGA GAA ACC TGC CAA GTA TG
R - GGT AGA AGA GTG AGT GTC GCT GTT G
58 139 [GenBank: U94889]
Acan = aggrecan; Adamts = a disintegrin and metalloproteinase with thrombospondin motifs; F = forward primer; Gapdh = glyceraldehyde 3-phosphate
dehydrogenase; Mmp = matrix metalloproteinase; R = reverse primer; Timp = tissue inhibitor of metalloproteinases.
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Page 3 of 13(Ambion, Austin TX, USA) following the manufacturers
guidelines. Aminoallyl-modified UTP was incorporated
and then labelled with reactive fluorophors Cy3 or Cy5
(GE Healthcare, Rydalmere, NSW, Australia). Duplicate
microarrays (Cy3/Cy5 dye-swap with replicate RNA sam-
ples) were performed for in vitro treatment (i.e. control
versus IL-1 at each time point), and sham versus MMD
(at one, two and six weeks). Labelled RNA was hybridized
to 44 k whole genome oligo microarrays (G4122A, Agilent
Technologies, Forest Hill, Victoria, Australia). The arrays
were scanned on an Axon 4000B scanner and features
extracted with GenePix Pro 4.1 software (Molecular
Devices, Sunnyvale, CA, USA). Raw data was processed
using a print-tip Loess normalization [23] using limma-
GUI software [24]. Mean log2-transformed expression
ratios and B-statistic values (log posterior odds ratio [23]
were calculated for all direct comparisons [25]. Data is
plotted as the average fold-change compared with control
for femoral head culture experiments, or average fold-
change with MMD compared with sham surgery at each
time point. The changes in S100a8 and S100a9 mRNA
expression in micro-dissected mouse tibial cartilage fol-
lowing MMD were validated by qRT-PCR in four separate
animals at each time point, and the median fold change in
MMD compared with sham-operated joints was calcu-
lated. These analyses were performed as previously
described [26] using mouse-specific primer pairs (S100a8
forward - TGCGATGGTGATAAAAGTGG, reverse -
GGCCAGAAGCTCTGCTACTC; S100a9 forward -
CACAGTTGGCAACCTTTATG, reverse - CAGCT-
GATTGTCCTGGTTTG), and the expression of S100a8
and S100a9 were normalized using the geometric mean
expression of two housekeeping genes [27], Atp5b (for-
ward - GGCTGATAAGCTGGCAGAAG, reverse - GGA-
GAGATCAGTTGCAGTGCT), and Rpl10 (forward -
TTGAAGACATGGTTGCTGAGA, reverse - AGGAC-
CACGATTGGGGATA). These two housekeeper genes
were shown by microarray expression profiling to be
unchanged during the onset and progression of OA in the
MMD mouse model (data not shown).
Immunolocalization of S100A8 and S100A9
Sections from archival paraffin blocks of male C57BL6
mouse knee joints with either AIA (7 and 28 days after
induction) or saline injection from a previous study [16]
were prepared at the same time as serial sections from
the mouse knee joints with surgically-induced OA.
Together with frozen sections from femoral head cul-
tures, slides were immunolocalized with polyclonal anti-
bodies to S100A8 and S100A9 (generously provided by
Professor Caroline Geczy [13] and Dr. Thomas Vogl
[9,12]). Immunostaining with the two different S100A8
and S100A9 antibodies gave similar results, and there-
fore only those obtained using the antibodies supplied
by Zreiqat and colleagues [13] are shown. Negative con-
trols included omitting the primary antibody or using
an equivalent concentration of rabbit immunoglobulin
(Ig)G as a control for nonspecific antibody binding.
Images representative of typical immunostaining in
mouse knee joints with either OA or AIA are presented.
The antibodies to S100A8 did not recognize recombi-
nant S100A9 on western blotting and vice versa (data
not shown); the anti-S100A8 and anti-S100A9 polyclo-
nal antibodies did not cross-react with human S100A12,
S100B or S100A1 [28,29]. The specificity of immunos-
taining was further validated by pre-absorption with 10
nmol of the recombinant proteins for one hour at room
temperature prior to immunolocalization.
Statistical analysis
Comparisons of parametric data were undertaken using
the unpaired Student’s t-test with Benjamini-Hochberg
correction for multiple comparisons [30]. Differential
expression in microarray analysis was assumed for B-
statistic of 1.0 or more [23].
Results
S100A8 and S100A9 immunolocalization in antigen
induced arthritis
As previously described [16] there is a complete loss of
proteoglycan staining in the non-calcified cartilage by
seven days post AIA induction (Figure 1). Chondrocytes,
particularly in the deep and to a lesser extent the super-
ficial zone of the non-calcified articular cartilage were
positive for S100A8, but not S100A9 in control (saline-
injected) joints. S100A8 reactivity remained positive in
the non-calcified cartilage in AIA joints, either at levels
similar to or increased compared with saline-injected
(non-inflamed) control joints (Figure 1). This positive
chondrocyte S100A8 staining was observed up to 28
days after induction of AIA even though there is signifi-
cant resolution of the synovial inflammation at this time
point [16]. Chondrocytes in the non-calcified articular
cartilage became immunopositive for S100A9 at seven
days after AIA induction, and remained positive at 28
days (Figure 1). Meniscal fibrochondrocytes showed
positive S100A8 and S100A9 immunostaining in AIA
joints at all times. Cells in the bone marrow of all joints
and inflammatory cells in the synovium (not shown)
and joint space (Figure 1, day seven) were also strongly
positive for S100A8 and S100A9.
Immunolocalization of S100A8 and S100A9 in mouse OA
Meniscal destabilization induced a progressive deteriora-
tion of the articular cartilage in the medial femoro-tibial
joint (Figure 2a) with no evidence of synovial inflamma-
tion as previously described [16]. Cartilage damage at
two weeks was characterized by a focal loss of
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tral weight-bearing region of the tibial plateau but no
structural damage. The area of proteoglycan loss
expanded with time and at eight weeks was accompa-
nied by evidence of surface fibrillation and some areas
of erosion. By 16 weeks there was full thickness erosion
of non-calcified cartilage to cover over 50% of the joint
surface.
There was no difference in immunostaining for
S100A8 and S100A9 between non-operated and sham-
operated joints at any time (results not shown) and
therefore only sham-operated results are included (Fig-
ure 2b). As described in saline-injected joints above,
chondrocytes throughout the non-calcified cartilage in
non-operated and sham-operated joints showed positive
staining for S100A8 (Figure 2b) but not S100A9 (not
shown). In marked contrast to the AIA model, with
induction of OA there was a loss of chondrocyte
S100A8 immunoreactivity in the non-calcified cartilage
compared with the corresponding sham-operated joint
(Figure 2b). The loss of S100A8 chondrocyte staining
extended beyond the area of proteoglycan loss defined
by decreased toluidine blue staining. Even at late stages
of OA with extensive cartilage erosion, chondrocytes in
the remaining intact cartilage in the load-bearing region
of the joint had reduced or lost S100A8 reactivity (Fig-
ure 2b, week 8 and 16). However, S100A8 reactivity was
still apparent in chondrocytes at the joint margins at all
time points, and in the calcified cartilage, bone marrow
and bone of developing and mature osteophytes (Figure
3). In contrast, chondrocytes showed little positive
S100A9 immunostaining in marginal regions in either
normal (non-operated or sham-operated) or OA joints,
although bone marrow and some osteocytes were posi-
tive (Figure 3).
Temporal changes in in vivo expression of S100 genes in
mouse OA
To determine whether the loss of S100A8 immunostain-
ing in cartilage in OA was due to decreased expression,
microarray mRNA expression profiling of the S100 pro-
tein family was performed [see Additional file 1]. The
expression of all S100 genes in chondrocytes in the
non-calcified articular cartilage at one, two and six
weeks post-induction of OA was determined and results
expressed as fold change compared with the sham-oper-
ated joints (Figure 4). The expression of a number of
S100 mRNAs including S100a5, S100a6, S100a8,





Figure 1 Toluidine blue/fast green and S100A8 and S100A9 immunostained paraffin sections of medial femoro-tibial compartments of
mouse knee joints from saline-injected compared with AIA at days 7 and 28. Scale bar = 100 μm. AIA = antigen-induced arthritis.
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Page 5 of 13Figure 2 Histopathological examination of osteoarthritic changes in mouse knee (femoro-tibial) joints following medial meniscal
destabilization (MMD). (a) Progressive cartilage damage at 2, 4, 8 and 16 weeks following medial meniscal destabilization-induced
osteoarthritis (OA) in mouse knee joints. Toluidine blue/fast green stained paraffin sections. Scale bar = 200 μm. (b) Serial sections stained with
toluidine blue or with S100A8 immunolocalization in mouse knees at different times following medial meniscal destabilization (MMD) or sham
surgery (at 16 weeks). Scale bar = 100 μm. Negative control sections were immunostained using an equivalent concentration of rabbit IgG.
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Page 6 of 13S100a9, S100a11, and S100b was significantly (B-statistic
≥ 1.0) regulated in chondrocytes following surgical
induction of OA. The most highly regulated were
S100a8 and S100a9, and, unlike other S100 family mem-
bers, they showed differential regulation with 7- to 14-
fold upregulation in early (week one and two) stages of
OA and a 7- to 18-fold decrease compared with sham-
operated levels in late-stage (week six) disease. The
change in S100a8 and S100a9 expression measured
using qRT-PCR showed some variability between the
individual animals. Nevertheless, three of the four ani-
mals at each time point showed the same direction (i.e.
increase or decrease) of change, and the median fold
change (n = 4) had a similar temporal pattern to that
observed in microarray analysis: 3.9- and 11-fold
increase in S100a8 and S100a9, respectively, in early
OA (two weeks), and a 16- and 25-fold decrease, respec-
tively, in late-stage (six weeks) MMD-induced OA.
In vitro regulation of S100A8 and S100A9
in mouse cartilage
In light of the distinct temporal change of S100 mRNAs,
and particularly S100a8 and S100a9, in chondrocytes in
OA, we investigated the regulation of expression of this
family of proteins during IL-1-induced degradation in
cartilage explants using microarray expression profiling
[see Additional file 2]. In contrast to the changes seen
in OA (Figure 4), chondrocyte expression of S100a5,
S100a6,a n dS100a11 was not regulated by IL-1 in vitro
(Figure 5a). S100a8 and S100a9 were both upregulated
by IL-1 at day four (10 and 9 fold, respectively) but not
day two, while expression of S100a4 was decreased by
IL-1 (about seven fold) at both two and four days (Fig-
ure 5a). At day 2, S100a8 and S100a9 protein was loca-
lized to the chondrocytes in control cultures, although
not all cells were positive (Figure 5b). In comparison to
the loss of S100A8 immunostaining seen in surgically-
induced OA (Figure 2b), the number and/or intensity of
chondrocyte S100A8 and S100A9 staining was increased
in IL-1-stimulated cartilage at day four, particularly in
flattened surface zone cells, such that all cells as well as
the surface matrix lamina were positively immunos-
tained for both proteins (Figure 5b). Weak staining of
calcified cartilage matrix but not chondrocytes or the
surface matrix was evident with equivalent concentra-
tions of rabbit IgG even in IL-1-stimulated cultures, and
staining was abolished pre-absorption with the recombi-
nant protein (Figure 5b).
S100A8 and S100A9, but not S100A8/S100A9 complexes
regulate chondrocyte gene expression
We sought to determine whether S100A8, S100A9, and/
or their heterodimeric complex had a similar pro-cata-
bolic effect in primary chondrocytes as previously
reported for S100A8 alone in a chondrocyte cell line [9].
We therefore compared mRNA expression of key
100µ
Figure 3 S100A8 and S100A9 immunostaining in cartilage and subchondral bone at the joint margins following sham operation or
medial meniscal destabilization at 4 and 16 weeks. Scale bar = 100 μm.
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in primary adult articular chondrocytes stimulated with
physiologically-relevant concentrations of S100A8,
S100A9, or their complex. Primary ovine chondrocytes
in monolayer culture maintained their anabolic chon-
drocyte phenotype with relatively high expression rela-
tive to Gapdh of aggrecan (3.0 ± 0.6), type II collagen
(3.0 ± 0.4), tissue inhibitors of metalloproteinases
(Timp)1 (1.4 ± 0.4), Timp2 (2.3 ± 0.3), and Timp3 (1.4
± 0.3) and generally low catabolic enzyme expression
(Adamts1 =0 . 9±0 . 1 ;Adamts4 =0 . 2±0 . 1 ;Adamts5 =
0.4 ± 0.1; Mmp1 = 0.06 ± 0.01, Mmp3 = 0.3 ± 0.1;
Mmp13 = 0.06 ± 0.03 and Mmp14 =1 . 8±0 . 0 6 ) .N o n e
of the genes examined were significantly regulated by
the heterodimeric S100A8/S100A9 complex (Figure 6).
In contrast, both S100A8 and S100A9 homodimers
caused a dose-dependent downregulation of chondro-
cyte aggrecan expression whereas Adamts1, Adamts4,
and Adamts5 mRNA levels were all significantly
increased (Figure 6). Collagen type II mRNA was signifi-
cantly decreased by S100A8 or S100A9, while Mmp1,
Mmp3, and Mmp13 were dose-dependently upregulated.
Timp1 and Timp3 mRNAs were largely unchanged,
while Timp2 mRNA levels were decreased by S100A8
and S100A9 (Figure 6). The pattern of most highly
upregulated genes by S100A8 and S100A9 (10
-7M) were
similar with, from most to least upregulated, Mmp13
then Mmp1 then Adamts4 then Mmp3 and finally
Adamts5.
Discussion
In this study S100A8 was immunolocalized in chondro-
cytes in normal murine articular cartilage in vivo,a n d
for the first time we showed that this intracellular
S100A8 is lost in OA. This contrasted sharply with the
retention or increase of S100A8 immunostaining in
chondrocytes in cartilage from inflammatory arthropa-
thies such as AIA. S100A9 protein was not detectable in
chondrocytes in the normal non-calcified region of the
articular cartilage, and although it increased in inflam-
matory arthritis, no chondrocyte or cartilage immunos-
taining was detected in OA. We found that the lack of
S100A8 and S100A9 protein localization in chondro-
cytes early in OA, was not associated with a decrease
but rather a significant increase in mRNA expression for
both proteins. Although increased chondrocyte mRNA
for S100a8 and S100a9 could be induced by IL-1 in
vitro, this was associated with an increase in cell and
cartilage matrix staining for the two proteins. Together
with the distinctly different chondrocyte expression pro-
file of other S100 proteins in IL-1-stimulated compared
with OA murine cartilage, this suggests that the early
upregulation of S100A8 and S100A9 in surgically-
induced OA was not due to increased IL-1 activity.
Importantly, increased mRNA levels for both S100a8
and S100a9 in early OA was associated with a loss of
cellular staining, suggesting that these S100 proteins
may be secreted from the cells and act as extracellular
signaling molecules. We have now shown that
Figure 4 Fold change in S100 gene expression measured by microarray expression profiling, in micro-dissected cartilage from
surgically-induced OA compared with sham-operated joints 1, 2 and 6 weeks post-operatively. Pooled samples were used from three
sham or medial meniscal destabilization (MMD) joints per time point. *B-statistic ≥ 1.0. OA = osteoarthritis; po = post-operatively.
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Page 8 of 13Figure 5 Changes in S100 proteins in cultured mouse articular cartilage. (a) Fold change in S100 gene expression, measured by microarray
expression profiling, in mouse femoral head cartilage cultured with or without IL-1 for two or four days compared with control cultures
measured by microarray expression profiling (pooled sample from three femoral heads/treatment/time). *B-statistic ≥ 1.0. (b) S100A8 and S100A9
immunostaining in frozen sections of mouse femoral head articular cartilage following four days of culture with IL-1. Substantial numbers of
chondrocytes did not stain with S100A8 and S100A9 in the control cultures (small arrows). In IL-1-stimulated cultures the intensity and
proportion of positively stained chondrocytes increased. In addition, the surface matrix lamina stained positive for both S100A8 and S100A9
(large arrows). Negative controls included sections of IL-1-stimulated cartilage incubated with equal concentration of IgG, or localized with anti-
S100A8 following pre-absorption with recombinant S100A8 protein. Scale bar = 100 μm.
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Page 9 of 13homodimeric S100A9 promotes increased catabolic
enzyme and decreased matrix protein gene expression
in chondrocytes very similar to that induced by the
S100A8 homodimer. In contrast, the heterodimeric
complex failed to alter chondrocyte metabolism, sug-
gesting that a dysregulation in expression and/or secre-
tion of the two subunits may play a significant role in
their potential bioactivity.
Taken together the above novel findings suggest that
the regulation of S100a8 and S100a9 expression and
secretion from chondrocytes could play a role in the
early stages of cartilage degradation in OA, and high-
light the significant differences in the pathogenesis of
cartilage destruction in OA versus inflammatory joint
diseases. The strong positive chondrocyte staining for
both S100A8 and S100A9 observed in AIA in the cur-
rent study was in accord with previously reported results
in this inflammatory arthritis model [9]. However, we
found that normal mouse articular chondrocytes were
positive for S100A8, the specificity of which was
Figure 6 Fold change (± SEM) compared with unstimulated cultures in gene expression measured by real-time qRT-PCR in primary
ovine chondrocytes cultured for 24 hours in monolayer with 10 or 100 nM S100A8, S100A9 or S100A8/S100A9 complex. n = 6 per
culture condition. * = significant difference compared with control cultures (P < 0.027).
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Page 10 of 13confirmed by the lack of staining with equivalent pre-
immune IgG and pre-absorption of the antibody with
recombinant S100A8. This positive S100A8 staining
contrasts with a previously reported lack of immunos-
taining in normal mouse knees [9], but is consistent
with positive S100A8 and S100A9 staining in murine
and human growth plate chondrocytes [13], and non-sti-
mulated H4 murine chondrocyte cells [9]. The reason
for this discrepancy is unclear but may relate to differ-
ences in staining sensitivity due to fixation, decalcifica-
tion, antibodies, and/or immunostaining methods used.
Indeed, in frozen sections of mouse femoral head carti-
lage we could show positive S100A9 as well as S100A8
staining. This different staining pattern in the femoral
head cartilage compared with adult joints, may be due
to the age of the mice from which the cartilage was
obtained, and/or that the tissue was cultured for four
days prior to immunostaining. Nevertheless, the results
are consistent with active synthesis of both S100A8 and
S100A9 proteins by chondrocytes in normal non-calci-
fied articular cartilage. The change in S100A8 immunos-
taining in surgically-induced mouse OA was restricted
to the load-bearing areas of articular cartilage, whereas
localization in other tissues and at the joint margins was
unaltered. This differed in AIA where increased menis-
cal staining for S100A8 and S100A9 was observed in
association with positive articular chondrocyte staining.
This suggests that local factors such as mechanical over-
loading of the cartilage, rather than humoral agents
affecting the whole joint such as cytokines or growth
factors, play a significant role in regulating the metabo-
lism of these proteins in cartilage in OA.
MMP-2 and MMP-9 have been shown to degrade
S100A8 and S100A9 [31] and both of these MMPs are
upregulated in OA cartilage [32,33] and could poten-
tially explain the loss of immunostaining in the mouse
model. It is also possible that the increased chondrocyte
S100a8 and S100a9 mRNA in early MMD-induced OA
was not translated into protein, through micro-RNA
silencing pathways predicted to act on the mRNA of
both genes [34,35]. However, we speculate that the loss
of chondrocyte immunostaining for both S100A8 and
S100A9 in early OA while mRNA expression for both
proteins is increased, may be due to their secretion from
the cell. S100A8 and S100A9 are released from macro-
phages and neutrophils during inflammation [6], and
this secretion is concomitant with loss of cellular immu-
nostaining [36], similar to that observed in the chondro-
cytes in the present study. S100A9 is released from IL-
1-stimulated mouse cartilage in vitro, while S100A8 is
not detected in this same conditioned media, suggesting
either differential release or extracellular processing/
degradation of the two proteins [37]. In the current
study there was evidence of extracellular release of
S100A9, and to a lesser extent S100A8, with positive
immunostaining in the surface matrix lamina of IL-1-sti-
mulated mouse femoral head cartilage (Figure 5b). How-
ever, the chondrocytes still remained strongly
immunopositive for both S100A8 and S100A9 in this
IL-1-stimulated cartilage despite secretion of the S100
proteins, which contrasts with lack of chondrocyte stain-
ing in OA mouse joints. To date, we have not been able
to confirm if there is increased soluble S100A8 or
S100A9 in articular cartilage in OA. It remains unclear,
therefore, whether release of S100A9 and/or S100A8
from chondrocytes occurs in early OA or with excessive
mechanical loading of cartilage.
Release of S100A8 and S100A9 proteins from chon-
drocytes into the extracellular space, would facilitate
their activity as cytokine-like molecules in early OA. We
showed that exogenous/extracellular S100A8, and for
the first time S100A9 homod i m e r ,c o u l dh a v ear o l ei n
initiating cartilage degradation by decreasing chondro-
cyte expression of aggrecan (Acan) and collagen II
(Col2a1), but increasing Adamts1, Adamts4, Adamts5,
Mmp1, Mmp3,a n dMmp13 mRNA levels. The increase
in metalloproteinase mRNA was not balanced by a simi-
lar increase in TIMPs, promoting a potential imbalance
in enzyme/inhibitor ratios and matrix degradation once
the pro-MMPs are activated. This is consistent with the
recent report showing increased aggrecanolysis in mur-
ine patella explant cultures stimulated with S100A8 [9].
The effects of S100A8 on primary ovine articular chon-
drocytes were in general agreement with that reported
in the synovium and macrophages [12], and the H4
murine chondrocyte cell line [9], although some subtle
differences were noted. We found no regulation of
Mmp14 by S100A8 in chondrocytes, whereas this
enzyme was upregulated in synovium [12]. It has been
suggested that the chondroprotection in inflammatory
arthritis in S100A9 knock-out mice could be due to the
concomitant lack of S100A8 in these animals [9]. Our
results have now shown that S100A9 homodimer itself
could play a role in cartilage breakdown by inducing
similar regulation of potential cartilage-degrading
enzymes in chondrocytes as S100A8.
Thus far there is no explanation as to why the hetero-
dimer is inactive and the homodimers are active in
chondrocytes. We speculate that the heterodimers may
require a trigger for activation in contrast to the homo-
dimers, which are constitutively active. For the murine
heterodimer one such trigger is LPS, and activation of
cells by LPS is amplified in the presence of the murine
heterodimer [11]. It has been suggested that S100A8/
S100A9 complex formation results in conformational
change and altered biological function of the individual
proteins [11,38]. Oligomerization of the heterodimer
with calcium/zinc binding may result in steric masking
Zreiqat et al. Arthritis Research & Therapy 2010, 12:R16
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Page 11 of 13of the receptor-binding epitope [38]. This is consistent
with the fact that S100A8/S100A9 complex failed to reg-
ulate gene expression in chondrocytes. Previously, how-
ever, the heterodimercomplex but neither homodimer
was found to be active in stimulating endothelial cells
[39], and the complex upregulated MMP13 in macro-
phages to a similar level as the S100A8 homodimer [12].
These divergent results suggest that the S100 proteins
may elicit distinct effects in different cell types within
the joint. It would be interesting in the future to deter-
mine whether these differential effects are driven by var-
iation in expression of potential receptors for these S100
proteins, such as cell-surface heparan sulfate proteogly-
cans [40] or toll-like receptor-4 (TLR4) [11], which are
expressed by chondrocytes [41,42]. TLR4 in particular
has been strongly implicated in joint inflammation and
cartilage destruction in experimental inflammatory
arthropathies in mice [43].
Conclusions
We have shown that extracellular S100A8 and S100A9
homodimers can both stimulate a degradative response
in articular chondrocytes. Dysregulation of the synthesis
and release of these two proteins by chondrocytes could
play a role in cartilage destruction in arthritis. However,
our studies comparing surgically-induced OA with AIA
in mice, suggests that although S100A8 and S100A9
may have a role in initiating early cartilage degradation
in both arthropathies, they are unlikely to have a signifi-
cant role in the ongoing cartilage degradation in
chronic/late-stage OA. Defining the differences in
pathophysiological pathways and mechanisms in differ-
ent arthritic conditions and in different stages of disease
is important in designing better therapies.
Additional file 1: Excel file containing the raw microarray data from the
Agilent 44 K arrays comparing the expression of S100 proteins in micro-
dissected non-calcified articular cartilage pooled from three separate
animals one, two and six weeks after medial meniscal destabilization or
sham surgery.
Click here for file
[http://www.biomedcentral.com/content/supplementary/ar2917-S1.xls]
Additional file 2: Excel file containing the raw microarray data from the
Agilent 44 K arrays comparing the expression of S100 proteins in femoral
head cartilage pooled from three separate cultures under control and IL-
1-stimulated conditions for two and four day.
Click here for file
[http://www.biomedcentral.com/content/supplementary/ar2917-S2.xls]
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